Back to Browse Journals » Journal of Inflammation Research » Volume 4

The role of the NLRP3 inflammasome in gout

Authors Sarah R Kingsbury, Philip G Conaghan, Michael F McDermott

Published Date March 2011 Volume 2011:4 Pages 39—49

DOI http://dx.doi.org/10.2147/JIR.S11330

Published 13 March 2011

Sarah R Kingsbury1,2, Philip G Conaghan1,2, Michael F McDermott1,2
1Section of Musculoskeletal Disease, Leeds Institute of Molecular Medicine 2NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK

Abstract: Gout is an inflammatory arthritis characterized by abrupt self-limiting attacks of inflammation caused by precipitation of monosodium urate crystals (MSU) in the joint. Recent studies suggest that orchestration of the MSU-induced inflammatory response is dependent on the proinflammatory cytokine IL-1ß, underlined by promising results in early IL-1 inhibitor trials in gout patients. This IL-1-dependent innate inflammatory phenotype, which is observed in a number of diseases in addition to gout, is now understood to rely on the formation of the macromolecular NLRP3 inflammasome complex in response to the MSU 'danger signal'. This review focuses on our current understanding of the NLRP3 inflammasome and its critical role in MSU-crystal induced inflammatory gout attacks. It also discusses the management of treatment-resistant acute and chronic tophaceous gout with IL-1 inhibitors; early clinical studies of rilonacept (IL-1 Trap), canakinumab (monoclonal anti-IL-1ß antibody), and anakinra have all demonstrated treatment efficacy in such patients.

Keywords: gout, inflammasome, NLRP3, IL-1

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Rilonacept in the management of cryopyrin-associated periodic syndromes (CAPS)

Justin Gillespie, Rebeccah Mathews, Michael F McDermott

Journal of Inflammation Research 2010, 3:1-8

Published Date: 19 January 2010

Readers of this article also read: